IMAC Holdings, Inc. is a clinical research and commercialization company focused on combining life science advancements with traditional medical care across oncology, neurological, and orthopedic specialties. Operating through its subsidiary Ignite Proteomics LLC, the company provides proteomic products and precision medicine services utilizing a patented phosphoprotein and protein biomarker platform. Its reverse phase protein array (RPPA) technology quantifies protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. IMAC Regeneration Centers deliver natural, non-opioid solutions for pain management, addressing demand for conservative treatments in an aging population. The company's laboratory developed tests are utilized by oncologists across the United States to assist in targeted treatment planning for patients with advanced breast cancer. Additionally, IMAC conducts clinical trials for investigational compounds, including umbilical cord-derived allogenic mesenchymal stem cells for neurological conditions. Headquartered in Franklin, Tennessee, IMAC Holdings serves as a bridge between precision diagnostics and personalized medical care in specialized healthcare markets.